HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 26, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 26, 2026.

A total of 17,355,806 Common Shares, or 55.49% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
John Welborn	16,086,394	99.28	117,463	0.72
Craig Millian	15,210,417	93.87	993,440	6.13
John Hanna	14,260,103	88.00	1,943,754	12.00
Rodney Hill	12,355,669	76.25	3,848,188	23.75
Norma Beauchamp	10,692,035	65.98	5,511,822	34.02
Kyle Dempsey	13,301,086	82.09	2,902,771	17.91
Christian Roy	14,318,102	88.36	1,885,755	11.64
Christine Elliott	15,197,317	93.79	1,006,540	6.21

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors with 16,273,112 votes (93.76%) cast "for" and 1,082,694 votes (6.24%) withheld.

Shareholders also approved the long-term incentive plan for the Company, with 16,802,842 votes (99.25%) cast "for" and 121,015 votes (0.75%) cast against.

ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting psychiatric disorders and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., [phone], [email protected]